Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553499 | 0.86 | ELANE (0.58) | NPC1RAB9AMAPTPSMB8ELANE | |
| SCHEMBL5720494 | 0.83 | NPC1 (0.50) | NPC1RAB9AMAPTPSMB8SMN1; SMN2 | |
| SCHEMBL1554271 | 0.82 | NPC1 (0.46) | NPC1RAB9AMAPTPSMB8ELANE | |
| SCHEMBL21488211 | 0.82 | ELANE (0.46) | NPC1RAB9AMAPTPSMB8ELANE | |
| SCHEMBL3913461 | 0.79 | NPC1 (0.50) | NPC1RAB9AMAPTPSMB8SMN1; SMN2 | |
| SCHEMBL1792867 | 0.78 | ELANE (0.58) | NPC1RAB9AMAPTPSMB8ELANE | |
| SCHEMBL23207497 | 0.76 | MAPT (0.47) | NPC1RAB9AMAPTPSMB8ELANE | |
| SCHEMBL29639834 | 0.76 | MAPT (0.47) | NPC1RAB9AMAPTPSMB8ELANE | |
| SCHEMBL30524315 | 0.76 | XDH (0.40) | NPC1RAB9AMAPTSMN1; SMN2TP53 | |
| SCHEMBL34471230 | 0.74 | MAPT (0.46) | NPC1RAB9AMAPTPSMB8ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106588807-B | Alkene compound containing gem-difluoromethylene and preparation method thereof | 上海大学 | 2020-04-03 | — | — | CN | claimed |
| CN-106749214-B | Compound containing 1, 3-benzoxazole difluoromethylene indolone and preparation method thereof | 上海大学 | 2020-01-17 | — | — | CN | claimed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-116621791-B | Fluorine-containing benzoxazole compound and synthesis method thereof | 上海大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-116621791-A | Fluorine-containing benzoxazole compound and synthesis method thereof | 上海大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-110114358-B | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2021-12-03 | — | — | CN | disclosed |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| CN-112312914-A | Therapeutic agent for inflammatory disease, autoimmune disease, fibrotic disease, and cancer disease | 明治制果药业株式会社 | 2021-02-02 | — | — | CN | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| CN-106588807-B | Alkene compound containing gem-difluoromethylene and preparation method thereof | 上海大学 | 2020-04-03 | — | — | CN | disclosed |
| CN-106588807-B | Alkene compound containing gem-difluoromethylene and preparation method thereof | 上海大学 | 2020-04-03 | — | — | CN | disclosed |
| CN-106749214-B | Compound containing 1, 3-benzoxazole difluoromethylene indolone and preparation method thereof | 上海大学 | 2020-01-17 | — | — | CN | disclosed |
| CN-106749214-B | Compound containing 1, 3-benzoxazole difluoromethylene indolone and preparation method thereof | 上海大学 | 2020-01-17 | — | — | CN | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| CN-102180841-B | 2-bromodifluoromethyl substituted 1,3-oxazoline compound and synthesis method thereof | UNIV SHANGHAI | 2013-01-09 | — | — | CN | disclosed |
| CN-102180841-A | 2-bromodifluoromethyl substituted 1,3-oxazoline compound and synthesis method thereof | UNIV SHANGHAI | 2011-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | REN, CYP11B1, CYP11B2 | NPC1 319/4885RAB9A 797/4885MAPT 3939/4885 |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | NPC1 291/4885RAB9A 907/4885MAPT 3178/4885 |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | CCR1, SSB, C5 | NPC1 3329/4885RAB9A 2786/4885MAPT 4782/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | NPC1 3329/4885RAB9A 2786/4885MAPT 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.